Nereus Pharmaceuticals, Inc., a San Diego, CA-based company focused on drug discovery and development from marine microbial sources, has raised $20m in financing.
The round was led HBM BioVentures, with participation from exisiting investors Forward Ventures, Alta Partners, Advent International, Roche Venture Fund, Gimv, Pacific Venture Group, and Astellas Venture Management.
This funding was provided in conjunction with the company’s progress of its clinical programs.
Nereus currently has two oncology drug candidates in clinical trials:
– Plinabulin (NPI-2358), a tumor vascular disrupting agent, is being evaluated in a Phase 2 trial for non-small cell lung carcinoma
– a proteasome inhibitor NPI-0052 is being evaluated in multiple Phase I trials for solid tumors, lymphomas and multiple myeloma.